Last reviewed · How we verify
BI 653048 BS H3PO4 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BI 653048 BS H3PO4 (BI 653048 BS H3PO4) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BI 653048 BS H3PO4 TARGET | BI 653048 BS H3PO4 | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BI 653048 BS H3PO4 CI watch — RSS
- BI 653048 BS H3PO4 CI watch — Atom
- BI 653048 BS H3PO4 CI watch — JSON
- BI 653048 BS H3PO4 alone — RSS
Cite this brief
Drug Landscape (2026). BI 653048 BS H3PO4 — Competitive Intelligence Brief. https://druglandscape.com/ci/bi-653048-bs-h3po4. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab